<?xml version="1.0" encoding="UTF-8"?>
<p id="p0240">Rituximab is another biologic drug that has been associated with an increased risk of certain infections. It is a chimeric, monoclonal antibody that targets CD20 on B-lymphocytes leading to rapid B cell depletion. Its use has been associated with reactivation of hepatitis B, severe 
 <italic>Pneumocystis jirovecii (carinii)</italic> infection, and progressive multifocal leukoencephalopathy (PML)Â [
 <xref rid="bib6" ref-type="bibr">6</xref>]. 
</p>
